A 38-year-old man with newly diagnosed seronegative rheumatoid arthritis (RF– and anti-CCP–) and moderate disease activity is starting disease-modifying antirheumatic drug (DMARD) therapy. What is the drug of choice for initial monotherapy?

Question

Accepted Answer

B. Methotrexate. ## First-Line csDMARD in Early RA

**Key Point:** Methotrexate is the anchor drug and gold standard first-line DMARD for all patients with RA, regardless of serology (seropositive or seronegative).

**High-Yield:** ACR and EULAR guidelines recommend starting methotrexate monotherapy in all newly diagnosed RA patients within 3 months of symptom onset, irrespective of RF or anti-CCP status.

### Methotrexate as First-Line DMARD

| Criterion | Methotrexate | Leflunomide | Sulfasalazine |
|-----------|--------------|-------------|---------------|
| **Efficacy in RA** | Excellent (60–70% remission) | Good (50–60% remission) | Moderate (40–50% remission) |
| **Onset of action** | 6–12 weeks | 8–12 weeks | 6–12 weeks |
| **Reversibility** | Yes (short half-life) | No (long half-life, washout needed) | Yes |
| **Pregnancy safety** | Teratogenic (avoid) | Teratogenic (avoid) | Safer in pregnancy |
| **Monitoring** | CBC, LFTs, renal function | CBC, LFTs | CBC, LFTs |
| **First-line status** | **YES** | Second-line | Second-line |

**Clinical Pearl:** Methotrexate is typically started at 10–15 mg/week (oral or SC) and titrated to 20–25 mg/week. Folic acid 5 mg daily (except on methotrexate day) reduces toxicity. Response is expected by 8–12 weeks.

**Mnemonic: MTX is the Anchor** — Methotrexate is the backbone of RA therapy; all other DMARDs are added to it, not instead of it.

### Why Not Biologics First?

**Warning:** Biologic TNF-α inhibitors are NOT first-line monotherapy in newly diagnosed RA. They are reserved for:
- Inadequate response to csDMARD monotherapy (after 3–6 months)
- High-risk disease (high disease activity + poor prognostic factors: RF+, anti-CCP+, early erosions)
- In some cases, combination with methotrexate from the start in high-risk seropositive disease

Using biologics as initial monotherapy is costly, unnecessary, and not guideline-recommended for standard-risk patients.

Answer

A. Biologic TNF-α inhibitor

Answer

C. Leflunomide

Answer

D. Sulfasalazine

A 38-year-old man with newly diagnosed seronegative rheumatoid arthritis (RF– and anti-CCP–) and moderate disease activity is starting disease-modifying antirheumatic drug (DMARD) therapy. What is the drug of choice for initial monotherapy?

Explanation

First-Line csDMARD in Early RA

Methotrexate as First-Line DMARD

Why Not Biologics First?

Practice similar questions

Join our NEET PG community

Criterion	Methotrexate	Leflunomide	Sulfasalazine
Efficacy in RA	Excellent (60–70% remission)	Good (50–60% remission)	Moderate (40–50% remission)
Onset of action	6–12 weeks	8–12 weeks	6–12 weeks
Reversibility	Yes (short half-life)	No (long half-life, washout needed)	Yes
Pregnancy safety	Teratogenic (avoid)	Teratogenic (avoid)	Safer in pregnancy
Monitoring	CBC, LFTs, renal function	CBC, LFTs	CBC, LFTs
First-line status	YES	Second-line	Second-line